DPPA4 Inhibitors are a class of compounds that target and inhibit the activity of the DPPA4 enzyme. The abbreviation DPPA4 stands for "Developmental Pluripotency-Associated Protein 4". This enzyme is part of the family of DPP proteins, which are known to have essential roles in various biological processes. DPPA4 itself is particularly known for its role in embryogenesis and cellular pluripotency. Pluripotent cells have the unique capability to differentiate into any cell type of the body, a property which is of central importance during the early stages of embryonic development.
The exact mechanism by which DPPA4 functions is still an area of active research. However, its association with pluripotency signifies its crucial role in maintaining the delicate balance between cellular differentiation and the preservation of a cell's undifferentiated state. Inhibitors of DPPA4, therefore, have the potential to modulate these cellular processes by acting on the enzyme's activity. The design and synthesis of DPPA4 inhibitors involve the understanding of the enzyme's structure, substrate specificity, and the molecular interactions that these compounds can exploit to effectively reduce or halt its activity. As with any enzyme inhibitor, the specificity, potency, and safety profile are essential parameters that drive research in this area. While the precise applications of these inhibitors can vary, their ability to modulate DPPA4's activity offers a unique window into understanding cellular differentiation processes and pluripotency regulation at a molecular level.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sitagliptin | 486460-32-6 | sc-482298 sc-482298A sc-482298B | 25 mg 100 mg 1 g | $213.00 $473.00 $733.00 | 10 | |
A selective, bioavailable DPP-4 inhibitor that enhances levels of incretin hormones. Increases active incretin, helping to lower blood sugar. | ||||||
Vildagliptin | 274901-16-5 | sc-208485 | 10 mg | $176.00 | 4 | |
Selectively inhibits DPP-4 enzyme activity, leading to increased levels of incretin hormones. Reduces blood sugar. | ||||||
Saxagliptin | 361442-04-8 | sc-473161 | 1 mg | $360.00 | ||
A selective DPP-4 inhibitor, augments postprandial insulin and decreases glucagon secretion. | ||||||
Linagliptin | 668270-12-0 | sc-364721 sc-364721A | 5 mg 10 mg | $260.00 $426.00 | 2 | |
Binds reversibly to DPP-4 and enhances the level of hormone incretin. Increases insulin secretion and reduces glucagon secretion. | ||||||
Gemigliptin tartrate | 1374639-74-3 | sc-507281 | 10 mg | $165.00 | ||
Increases incretin levels, leading to improved glucose-dependent insulin secretion and reduced glucagon secretion. | ||||||
Anagliptin | 739366-20-2 | sc-507278 | 5 mg | $280.00 | ||
Selectively inhibits the DPP-4 enzyme, boosts incretin hormone levels, encourages insulin secretion, and minimizes glucagon secretion under hyperglycemic conditions. | ||||||
Teneligliptin | 760937-92-6 (free base) | sc-475074 | 25 mg | $260.00 | 1 | |
Has a triazolopyridine structure. Binds covalently to the DPP-4 enzyme, causing a prolonged inhibitory effect on DPP-4 and increasing incretin levels. | ||||||
Trelagliptin | 865759-25-7 | sc-507285 | 5 mg | $405.00 | ||
Binds to DPP-4 in a manner that leads to sustained inhibition, raising incretin levels over a week. | ||||||
Omarigliptin | 1226781-44-7 | sc-507282 | 5 mg | $337.00 | ||
Designed for once-weekly dosing, effectively inhibits DPP-4, thus elevating incretin hormone levels and promoting better glucose control. | ||||||
Evogliptin | 1222102-29-5 | sc-507284 | 5 mg | $1060.00 | ||
Functions by selectively inhibiting DPP-4, thereby increasing postprandial insulin and decreasing glucagon concentrations. | ||||||